Enjoy complimentary customisation on priority with our Enterprise License!
The autoinjectors market size is estimated to grow at a CAGR of 25.14% between 2022 and 2027. The autoinjectors market size is forecast to increase by USD 134,014.58 million. The growth of the market depends on several factors, including the increasing prevalence of allergies and need for immediate care, the growing popularity of injectable therapies, and the rise in commercial approvals of new products.
This autoinjectors market report extensively covers market segmentation by application (anaphylaxis, multiple sclerosis, rheumatoid arthritis, and diabetes), end-user (hospitals and clinics, and self-administration), and geography (North America, Europe, Asia, and Rest of World (ROW)). It also includes an in-depth analysis of drivers, trends, and challenges. Furthermore, the report includes historic market data from 2017 to 2021.
To learn more about this report, View Report Sample
The increasing prevalence of allergies and need for immediate care are notably driving the market growth, although factors such as side-effects of autoinjectors may impede the market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
Increasing prevalence of allergies and need for immediate care is the key factor driving the growth of the global autoinjectors market. Globally, the prevalence of allergies to food items, pollens, food additives, latex, and dust and the risk of contracting anaphylaxis caused by these factors are increasing. According to CDC, allergies are the sixth leading cause of chronic illness in the US, with an annual expenditure of more than $18 billion. More than 50 million North American are affected by allergies each year. On average, 30%-35% of the global population is diagnosed with an allergy annually. Canada is witnessing an increase in healthcare spending that will further propel the North American market during the forecast period.
The Brazilian auto-injector market is expected to grow during the forecast period, owing to the country's economic growth, improved access to remote medical facilities, and rising awareness of auto-injectors in the country. The high prevalence of anaphylaxis in the United States leads to high adoption of generic epinephrine auto-injectors. Autoinjectors can treat symptoms with a small dose of epinephrine. These autoinjectors help restore normal breathing, increase blood pressure if it is dropping, and reduce swelling. With the increasing occurrence of allergies, the growth prospects of epinephrine autoinjectors are likely to rise, as they can be self-administered during sudden anaphylactic attacks. Therefore, the increasing prevalence of allergies and the need for immediate care will boost the growth of the global autoinjectors market during the forecast period.
Strategic alliances between companies is the primary trend in the global autoinjectors market. Strategic alliances in the global autoinjector market are on the rise, with several acquisitions/partnerships aimed at expanding the business by offering new mineral cosmetics. For instance, Pfizer Inc. works in association with Antares Pharma to develop an autoinjector pen for an undisclosed Pfizer drug. Pfizer product utilizes Antares Pharma patented QuickShot autoinjector and an unrevealed drug.
Moreover, Pfizer Inc. will obtain the US FDA approval and marketing permission for the combination product in the coming years. The development agreement between Antares Pharma and Pfizer aims to expand the portfolio of pipeline partners' products. Further, such strategic alliances will help Pfizer Inc. increase the potential number of products utilizing Antares Pharma innovative QuickShot autoinjector technology platform. Thus, an increase in strategic alliances is expected to boost the growth of the global autoinjectors market during the forecast period.
Side-effects of autoinjectors is a major challenge to the growth of the global autoinjectors market. Using autoinjectors causes several side effects such as infections, high and low blood pressure, muscle pain, headache, and diarrhea. Patients with chemotherapy-induced anemia show an increased incidence of fatigue, edema, nausea, vomiting, fever, and hypertension. MS patients administered with autoinjectors are vulnerable to severe hepatic injury, including cases of hepatic failure. In certain cases, interferon beta-1 b-filled autoinjectors for such patients can also cause anaphylaxis.
Other allergic reactions may include dyspnea, bronchospasm, tongue edema, skin rash, and urticaria. Thus, the associated side effects can impact the adoption of autoinjectors and encourage patients to opt for alternatives with less severe side effects. Thus, the side effects of autoinjectors are expected to be slowed down the growth of the global autoinjectors market during the forecast period.
The report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Autoinjectors Market Customer Landscape
Vendors are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
AbbVie Inc.: The company offers autoinjectors namely, Adalimumab. Also, under this segment, the company conducts research and development, manufacturing, commercialization and sale of innovative medicines and therapies to allocate resources and assess business performance on a global basis in order to achieve established long-term strategic goals.
The report also includes detailed analyses of the competitive landscape of the market and information about 15 market vendors, including:
Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.
The market share growth by the anaphylaxis segment will be significant during the forecast period. The anaphylaxis segment generates the highest revenue because of the increasing prevalence of anaphylaxis and food allergies at a global level. For instance, according to the Centers for Disease Control and Prevention (CDC), around 8% of children in the US have food allergies.
Get a glance at the market contribution of various segments View the PDF Sample
The anaphylaxis segment was valued at USD 19,989.44 million in 2017 and continued to grow until 2021. Anaphylaxis is an acute, potentially fatal condition that is often a response to an allergen. One of the most effective treatments for anaphylaxis is the intramuscular administration of epinephrine, and it is the first line of treatment drugs. There are many auto-injector suppliers in the global market that offer epinephrine auto-injectors specifically for anaphylaxis. Therefore, the availability in the market of auto-injectors that enable self-administration of anaphylaxis medications and vendor support in demonstrating the process of self-administration are expected to propel this segment, making it the global automotive market.
For more insights on the market share of various regions Download PDF Sample now!
North America is estimated to contribute 41% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. Canada is witnessing an increase in healthcare spending that will further propel the North American market during the forecast period. The Brazilian auto-injector market is expected to grow during the forecast period, owing to the country's economic growth, improved access to remote medical facilities, and rising awareness of auto-injectors in the country. The high prevalence of anaphylaxis in the United States leads to high adoption of generic epinephrine auto-injectors. With the availability of the generic EpiPen, a product of Mylan, at affordable price points, the sales volume of epinephrine autoinjectors is expected to increase in the US market, boosting the market growth.
The outbreak of COVID-19 had a significant impact on the autoinjectors market in North America in 2020. However, in 2021, due to the large-scale vaccination drives implemented across the region, several business and industrial activities resumed, including the manufacturing of autoinjectors. Furthermore, the expansion of telemedicine services and the remote monitoring of patients has increased the demand for autoinjectors as patients require more convenient and accessible healthcare solutions. All these factors are expected to boost the growth of the autoinjectors market in North America during the forecast period.
The autoinjectors market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027.
Technavio categorizes the global autoinjectors market as a part of the global pharmaceuticals market within the overall healthcare industry. The parent global pharmaceuticals market covers products and companies engaged in the R&D or production of generic drugs, non-generic drugs, and veterinary drugs. Our market research report has extensively covered external factors influencing the parent market growth during the forecast period.
Autoinjectors Market Scope |
|
Report Coverage |
Details |
Page number |
165 |
Base year |
2022 |
Historic period |
2017-2021 |
Forecast period |
2023-2027 |
Growth momentum & CAGR |
Accelerate at a CAGR of 25.14% |
Market growth 2023-2027 |
USD 134,014.58 million |
Market structure |
Fragmented |
YoY growth 2022-2023(%) |
24.1 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 41% |
Key countries |
US, Canada, UK, Germany, and China |
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
Key companies profiled |
AbbVie Inc., Amgen Inc., Bayer AG, Becton Dickinson and Co., Eli Lilly and Co., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Halozyme Therapeutics Inc., Johnson and Johnson Services Inc., Johnson Medtech LLC, medmix Ltd., Merck KGaA, Owen Mumford Ltd., Pfizer Inc., RAVIMED Sp. zoo, Recipharm AB, SHL Medical AG, Teva Pharmaceutical Industries Ltd., Viatris Inc., and Ypsomed AG |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Application
7 Market Segmentation by End-user
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.